Publication

Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease.

Karalliedde, Janaka
Winocour, Peter
Chowdhury, Tahseen A
De, Parijat
Frankel, Andrew H
Montero, Rosa M
Pokrajac, Ana
Banerjee, Debasish
Dasgupta, Indranil
Fogarty, Damian
... show 6 more
Abstract
A significant percentage of people with diabetes develop chronic kidney disease and diabetes is also a leading cause of end-stage kidney disease (ESKD). The term diabetic kidney disease (DKD) includes both diabetic nephropathy (DN) and diabetes mellitus and chronic kidney disease (DM CKD). DKD is associated with high morbidity and mortality, which are predominantly related to cardiovascular disease. Hyperglycaemia is a modifiable risk factor for cardiovascular complications and progression of DKD. Recent clinical trials of people with DKD have demonstrated improvement in clinical outcomes with sodium glucose co-transporter-2 (SGLT-2) inhibitors. SGLT-2 inhibitors have significantly reduced progression of DKD and onset of ESKD and these reno-protective effects are independent of glucose lowering. At the time of this update Canagliflozin and Dapagliflozin have been approved for delaying the progression of DKD. The Association of British Clinical Diabetologists (ABCD) and UK Kidney Association (UKKA) Diabetic Kidney Disease Clinical Speciality Group have undertaken a literature review and critical appraisal of the available evidence to inform clinical practice guidelines for management of hyperglycaemia in adults with DKD. This 2021 guidance is for the variety of clinicians who treat people with DKD, including GPs and specialists in diabetes, cardiology and nephrology.
Citations
Altmetric:
Date
2022-01-26
Type
Article
Subject
Diabetes
Citation
Karalliedde J, Winocour P, Chowdhury TA, De P, Frankel AH, Montero RM, Pokrajac A, Banerjee D, Dasgupta I, Fogarty D, Sharif A, Wahba M, Mark PB, Zac-Varghese S, Patel DC, Bain SC. Clinical practice guidelines for management of hyperglycaemia in adults with diabetic kidney disease. Diabet Med. 2022 Apr;39(4):e14769. doi: 10.1111/dme.14769.
Journal / Source Title
Diabetic Medicine
DOI
10.1111/dme.14769
PMID
35080257
Publisher
Wiley
Publisher’s URL
Publisher’s statement
Note / Copyright